A patent battle between the University of California and the Massachusetts Institute of Technology (MIT) has cast a cloud over the ownership of the CRISPR gene-editing technology potentially worth billions of dollars. Bio-pharma companies, investors and researchers should use caution when navigating the complex intellectual property landscape.
CRISPR, an acronym for “clustered regularly interspaced short palindromic repeats” relies on an enzyme called Cas9 that uses a guide RNA molecule to home in on its target DNA, then it edits the DNA to disrupt genes or insert desired sequences. Just like PCR was in the 1980s, CRISPR is a game changer in molecular biology. It is faster, cheaper and easier to use than any other gene-editing technology.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
